CA Patent

CA2884795C — Formulations of enzalutamide

Assigned to Astellas Pharma Inc · Expires 2023-10-17 · 3y expired

What this patent protects

There is provided herein a formulation of a solid dispersion containing amorphous enzalutamide and hydroxypropyl methylcellulose acetate succinate and their its use for treating hyperproliferative disorders.

USPTO Abstract

There is provided herein a formulation of a solid dispersion containing amorphous enzalutamide and hydroxypropyl methylcellulose acetate succinate and their its use for treating hyperproliferative disorders.

Drugs covered by this patent

Patent Metadata

Patent number
CA2884795C
Jurisdiction
CA
Classification
—
Expires
2023-10-17
Drug substance claim
No
Drug product claim
No
Assignee
Astellas Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.